Anti-Human CD25 (Camidanlumab)

Humanized antibody derived from mouse clone targeting CD25

This biosimilar antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant biosimilar antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2-8°C Wet Ice

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Camidanlumab but is not linked to the toxin warhead SG3199. Camidanlumab antibody activity is directed against Human CD25.

CD25 is the alpha-chain of the interleukin-2 receptor¹, which regulates normal immune function², and is involved in signal transduction, cell growth and survival¹. CD25 is considered an attractive target for conjugated antibody chemotherapeutic development because it is overexpressed in various hematologic malignancies and is associated with poor prognosis.

Antibody drug conjugates (ADC) use tumor-associated surface antigens to specifically target cancer cells with cytotoxic agents. Human therapeutic grade Camidanlumab is an ADC composed of a human CD25-directed antibody (HuMax-TAC) that is maleimide- conjugated at reduced interchain cysteines via a cathepsin-cleavable valine-alanine linker to a PBD toxin warhead (SG3199)³.

Camidanlumab has a strong binding affinity to CD25-positive human anaplastic large cell lymphoma derived cell lines. This research grade biosimilar has the same specificity as the original therapeutic antibody but lacks the conjugated PBD toxin warhead.

CD25 is expressed by approximately 30% of human peripheral blood B cells, particularly those belonging to the memory B cell population. Additionally, CD25 is expressed on the cell surface of many lymphomas, including classical Hodgkin lymphoma and non-Hodgkin lymphoma.

IL-2

1 Epperla N, Hamadani M. Curr Hematol Malig Rep. 16(1):19-24. 2021.
2 Zammarchi F, Havenith K, Bertelli F, et al. J Immunother Cancer. 8(2):e000860. 2020.
3 Flynn MJ, Zammarchi F, Tyrer PC, et al. Mol Cancer Ther. 15(11):2709-2721. 2016.